Do Some Diabetes Drugs Reduce the Risk of Alzheimer’s?

MINNEAPOLIS – People taking certain drugs to lower blood sugar for type 2 diabetes had less amyloid in the brain, a biomarker of Alzheimer’s disease, when compared to both people with type 2 diabetes not taking the drugs and people without diabetes. The new study, published in the August 11, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology, also found people taking these drugs, called dipeptidyl peptidase-4 inhibitors, showed slower cognitive decline than people in the other two groups.

Alzheimer’s microbe hypothesis gets major NIH funding

After years of paltry funding, research on the possible role of microbes in the causation of Alzheimer’s disease will now get a major infusion of grants from the NIH’s National Institute on Aging

Drug-Induced Liver Injury, Translational microRNA Biomarkers, and More Featured in January 2021 Toxicological Sciences

in the January 2021 issue, Toxicological Sciences offers an engaging slate of research in toxicology, from endocrine toxicology and biomarkers to genetic and epigenetic toxicology and mixtures toxicology.

UCI-led study finds modifiable risk factors could play a role in Alzheimer’s disease

Amyloid is a key feature of Alzheimer’s disease, but the accumulation of these sticky proteins may not be the only risk factor for developing Alzheimer’s disease, according to a new study published this week. Other, modifiable risk factors, such as the amount of fats in our blood and how efficiently our bodies generate energy could also play important roles.